Fnu Saba Mushtaq, MD
Family Medicine · Dallas, TXNPI 1295221232
Payments from drug & device makers
Across 247 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$739
- Lilly USA, LLC$510
- AstraZeneca$466
- Novo Nordisk$441
- GSK$397
- Pfizer$222
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,358100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $739 |
| Lilly USA, LLC | 29 | $510 |
| AstraZeneca | 26 | $466 |
| Novo Nordisk | 28 | $441 |
| GSK | 24 | $397 |
| Pfizer | 13 | $222 |
| Novartis | 11 | $195 |
| Amgen | 11 | $185 |
| Otsuka America Pharmaceutical, Inc. | 8 | $153 |
| Boehringer Ingelheim | 8 | $145 |
| Idorsia Pharmaceuticals US Inc | 8 | $133 |
| Abbott | 5 | $109 |
| Exact Sciences | 6 | $108 |
| E.r. Squibb & Sons, L.L.C. | 3 | $68 |
| Johnson & Johnson | 4 | $67 |
| Corcept Therapeutics | 3 | $67 |
| Merck | 3 | $53 |
| Dynavax Technologies Corporation | 3 | $46 |
| Mylan Specialty L.p. | 3 | $41 |
| Lundbeck LLC | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $30 |
| Viatris Specialty LLC | 2 | $29 |
| Medtronic | 1 | $25 |
| OWP Pharmaceuticals, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $14 |
How this compares
$4,358 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $64,131 |
| JardianceEmpagliflozin | 41 | $52,807 |
| EliquisApixaban | 56 | $51,792 |
| FarxigaDapagliflozin Propanediol | 48 | $40,243 |
| MounjaroTirzepatide | 25 | $25,934 |
| RybelsusSemaglutide | 13 | $23,873 |
| XareltoRivaroxaban | 36 | $23,634 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $21,474 |
| JanuviaSitagliptin Phosphate | 13 | $19,748 |
| Repatha SureclickEvolocumab | 31 | $17,074 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $6,468 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,355 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $5,897 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $4,742 |
| Atorvastatin Calcium | 521 | $3,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $441 | $88,00570 claims |
| Boehringer IngelheimJardiance | $145 | $52,80741 claims |
| PfizerEliquis | $222 | $51,79256 claims |
| AstraZenecaFarxiga, Symbicort | $466 | $46,59873 claims |
| Lilly USA, LLCMounjaro | $510 | $25,93425 claims |
| Johnson & JohnsonXarelto | $67 | $23,63436 claims |
| GSKTrelegy Ellipta | $397 | $21,47432 claims |
| MerckJanuvia | $53 | $19,74813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dallas
- Thomas KingDallas$12M
- Jennifer ZonDallas$5.9M
- Chrisette DharmagunaratneDallas$5.6M
- Michele ReynoldsDallas$3.8M
- Shiwali RaiDallas$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.